Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions

Dabigatran, rivaroxaban, apixaban, and edoxaban are direct oral anticoagulants (DOACs) that are increasingly used worldwide. Taking into account their widespread use for the prevention of thromboembolism in cardiology, neurology, orthopedics, and coronavirus disease 2019 (COVID 19) as well as their...

Descripción completa

Detalles Bibliográficos
Autores principales: Shnayder, Natalia A., Petrova, Marina M., Shesternya, Pavel A., Savinova, Alina V., Bochanova, Elena N., Zimnitskaya, Olga V., Pozhilenkova, Elena A., Nasyrova, Regina F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143539/
https://www.ncbi.nlm.nih.gov/pubmed/33922084
http://dx.doi.org/10.3390/biomedicines9050451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143539/
https://www.ncbi.nlm.nih.gov/pubmed/33922084
http://dx.doi.org/10.3390/biomedicines9050451

Ejemplares similares